Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1995-7-18
|
pubmed:abstractText |
Reactions of the [D-serine]8-cyclosporin (2) with a series of alkylating agents under phase transfer conditions gave the alkylated products 3-6. Alkylations of 2 with hindered esters of bromoacetate gave the crystalline esters 7 and 8. Hydrolysis under basic conditions gave the acid 10. Reduction of ester 8 led to a novel cyclosporin 11. This was transformed in two additional steps to 15. In a similar two-step sequence 17 was prepared from 15. From 2 and methyl 2-(bromomethyl)acrylate product 20 was obtained. Alkylation of 2 with 49 followed by deprotection yielded 24. The linear isomer 27 was prepared. The 3-hydroxypropyl ether 30 was prepared in two steps from 28. The 4-hydroxybutyl ether 31 was accessible from 2 and 1,4-dibromobutane. The hydroxy group of 11 was converted to the tosylate 32. Base treatment of 32 led to the bicyclic [3(R)-morpholinecarboxylic acid]8-cyclosporin (39). The [2-ethoxy-5-morpholinecarboxylic acid]8-cyclosporin 40 was prepared via 36. Base treatment of the bromoacetate 37 gave the morpholinone derivative 41. [4(R)-Oxazolidinecarboxylic acid]8-cyclosporin (42) was obtained from 2 and methylene bromide. From 24 the tosylate 38 was prepared and cyclized to the hexahydrooxazepine derivative 43. [2(R)- Piperidinecarboxylic acid]8-cyclosporin (49) was prepared from 42 and 2(R)-piperidinecarboxylic acid 45 via 46-48. The bicyclic cyclosporin 39 was found to be about 3-4 times more active than cyclosporin A in our in vitro tests.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
26
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1853-64
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7783117-Alkylation,
pubmed-meshheading:7783117-Amino Acid Sequence,
pubmed-meshheading:7783117-Animals,
pubmed-meshheading:7783117-Antibody Formation,
pubmed-meshheading:7783117-Cyclosporins,
pubmed-meshheading:7783117-Ethers,
pubmed-meshheading:7783117-Female,
pubmed-meshheading:7783117-Immunosuppressive Agents,
pubmed-meshheading:7783117-Interleukin-2,
pubmed-meshheading:7783117-Lymphocyte Activation,
pubmed-meshheading:7783117-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:7783117-Lymphocytes,
pubmed-meshheading:7783117-Mice,
pubmed-meshheading:7783117-Mice, Inbred BALB C,
pubmed-meshheading:7783117-Mice, Inbred CBA,
pubmed-meshheading:7783117-Molecular Sequence Data,
pubmed-meshheading:7783117-Structure-Activity Relationship
|
pubmed:year |
1995
|
pubmed:articleTitle |
Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
|
pubmed:affiliation |
Sandoz Ltd., Basel, Switzerland.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|